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Background & Aims: During hepatic fibrogenesis, the he-
patic extracellular matrix changes to fibrillar collagens
types I and III, and cirrhosis is believed to produce an
irreversible scar. In this study, we investigated whether
gene delivery of human matrix metalloproteinase-1,
which degrades collagens types I and type III, would
attenuate established hepatic fibrosis in the rat, induced
by either thioacetamide or bile duct ligation. Methods:
Hepatic fibrosis induced by thioacetamide for 7 weeks
was persistent for at least 2 months, even after discon-
tinuation of the treatment. The rats were infected once
with a recombinant adenovirus, Ad5MMP-1, into which
human pro–human matrix metalloproteinase-1 comple-
mentary DNA was packaged, or with a control adenovi-
rus, Ad5LacZ. Results: In Ad5MMP-1–infected, but not in
Ad5LacZ-infected, rats, the fibrosis was dramatically at-
tenuated at 2 weeks after the infection. It is interesting
to note that the number of activated hepatic stellate
cells was also decreased in Ad5MMP-1–infected rats.
Moreover, disorganization of the hepatic trabecula, het-
erogeneity in the size of hepatocytes, and increased
dried liver weight were observed only in Ad5MMP-1–
treated rats, suggesting that human matrix metallopro-
teinase-1 stimulated hepatocyte proliferation, which
was confirmed by bromodeoxyuridine staining. After 4
weeks, the proliferative effect of human matrix metal-
loproteinase-1 almost disappeared, but the hepatic fi-
brosis remained attenuated, whereas the fibrosis in
Ad5LacZ-treated rats persisted. Furthermore, the ad-
ministration of Ad5MMP-1, but not Ad5LacZ, decreased
type I collagen and generated a small collagen fragment
in hepatic fibrosis induced by bile duct ligation.
Conclusions: Our findings show that transient human
matrix metalloproteinase-1 overexpression in the liver
effectively attenuates established fibrosis and induces
hepatocyte proliferation.
Hepatic fibrogenesis is characterized by increaseddeposition of extracellular matrix (ECM), such as
fibrillar collagens type I and type III.1,2 The major source
of these newly synthesized collagens is hepatic stellate
cells (HSCs) activated by a variety of fibrogenic stimuli.3
The key enzymes in the degradation of fibrillar collagens
are matrix metalloproteinase (MMP)-1 in humans and
MMP-13 in rats.4,5 However, during fibrogenesis, the
expression of MMP-1 or MMP-13 is very limited,
whereas that of MMP-2 increases.6–8 Moreover, fibrotic
livers also have high expression of the tissue inhibitors of
metalloproteinase (TIMPs), including TIMP-1 and
TIMP-2.9,10 Thus, there is a combination of low expres-
sion of interstitial collagenases and high TIMPs that
prevents degradation of the fibrillar collagens.
Another important factor in hepatic fibrogenesis is a
balance between urokinase plasminogen activator (uPA)
and plasminogen activator inhibitors.11 Plasmin, which
is generated by uPA, degrades ECM both directly and
indirectly by activation of MMPs. Plasminogen activator
inhibitor-1 expression is increased in activated HSCs and
in experimental cirrhotic livers concomitant with in-
creased expression of uPA and its receptor, whereas plas-
minogen activator inhibitor-1 messenger RNA levels are
unchanged in mild fibrosis.12 Indeed, the plasma con-
centration of plasminogen activator inhibitor-1 is in-
creased in patients with chronic liver diseases.13
Cirrhosis is generally considered to be stable even after
the removal of the fibrotic stimuli, whereas mild liver
fibrosis is sometimes reversible.14 Several approaches
have been reported in experimental animals to prevent
the progression of liver fibrosis15–21 or to reverse ad-
vanced liver fibrosis with hepatocyte growth factor.22,23
However, to date, no effective therapy for hepatic fibrosis
has been developed.
Abbreviations used in this paper: Ad5, adenovirus type 5; APMA,
p-aminophenylmercuric acetate; BrdU, bromodeoxyuridine; ECM, ex-
tracellular matrix; HSC, hepatic stellate cell; MMP, matrix metallopro-
teinase; PAGE, polyacrylamide gel electrophoresis; pfu, plaque-form-
ing unit; SDS, sodium dodecyl sulfate; SMA, smooth muscle actin; TAA,
thioacetamide; TIMP, tissue inhibitor of metalloproteinase; uPA, uroki-
nase plasminogen activator.




Our hypothesis is that failure to resolve the fibrous
scar results from the imbalance between too few inter-
stitial collagenases (MMP-1 or MMP-13) and too much
ECM and too many TIMPs. Furthermore, we propose
that the aberrant matrix of the fibrous scar maintains the
HSC in the activated state. We tested this hypothesis by
transiently changing the balance by using gene therapy
to deliver MMP-1 in a rat model of persistent liver
fibrosis.
Materials and Methods
Construction of the Recombinant
Adenovirus Ad5MMP-1
The recombinant replication-deficient adenovirus
Ad5MMP-1 was constructed by the methods of Bett et al.24 In
brief, plasmid pRc/CMV-pro-MMP-1, which contains a hu-
man pro–MMP-1 complementary DNA,25 was subcloned into
the SalI/HindIII site of the pACCMV.PLPASR () plasmid to
construct the plasmid pACCMV/MMP-1, in which pro–
MMP-1 is driven by the cytomegalovirus promoter/enhancer.
The recombinant adenovirus was then constructed by cotrans-
fection of the 293 embryonic human kidney cell line with the
pACCMV/MMP-1 plasmid plus the purified fragment of ClaI-
digested DNA from E1-deleted adenovirus type 5 (Ad5). The
human pro–MMP-1 sequence packaged into the recombinant
Ad5 virus (Ad5MMP-1) was confirmed by polymerase chain
reaction and by Western blotting. Ad5MMP-1 was grown in
293 cells and purified by banding twice on CsCl gradients.
Viral titers were determined by optical densitometry (particles
per milliliter) and by plaque assay, and recombinant virus was
then stored in 10% (vol/vol) glycerol at 20°C. Ad5LacZ,
which contains the Escherichia coli -galactosidase gene, was
also grown and purified as described previously and used as a
control virus.
Western Blot Analysis
Culture medium of Rat-2 fibroblasts infected with
Ad5MMP-1 (multiplicity of infection, 25) for 48 hours was
collected, concentrated with Centriplus (Amicon Inc., Beverly,
MA), and stored at 80°C for later analysis. To confirm that
expressed human pro–MMP-1 was correctly activated by its
activator, some of the culture medium was incubated with
p-aminophenylmercuric acetate (APMA; 1 mmol/L) at 37°C
for 4 hours and used for Western blot analysis. Liver tissues
from rats infected with Ad5MMP-1 (5  109 plaque-forming
units [pfu]) for 72 hours were homogenized in lysis buffer (10
mmol/L of HEPES [pH 7.9], 0.42 mol/L of NaCl, 1.5 mmol/L
of MgCl2 , 0.5 mmol/L of dithiothreitol, 0.5% Nonident P-40,
and 25% glycerol) with protease inhibitors at 4°C, followed by
rotating the tubes for 30 minutes at 4°C. After centrifugation,
cleared tissue lysates were collected and stored at 80°C for
later analysis. Lysate containing 20 g of protein was separated
by electrophoresis on 10% acrylamide sodium dodecyl sulfate
(SDS) gels and transferred to polyvinylidene difluoride mem-
branes as described previously.26 Equal loading was confirmed
by Ponceau S staining. Human MMP-1 was detected by using
rabbit anti–MMP-1 antibody (Chemicon International Inc.,
Temecula, CA). Blots were blocked in blocking buffer (5%
nonfat dry milk in PBST [phosphate-buffered saline contain-
ing 0.05% Tween 20]) for 1 hour, incubated overnight at 4°C
in primary antibody, diluted 1:1000 in blocking buffer, and
then diluted 1 hour with horseradish peroxidase–conjugated
goat anti-rabbit secondary antibody (Amersham Corp., Arling-
ton Heights, IL) diluted 1:1000 in blocking buffer. Proteins
were detected with enhanced chemiluminescence detection
reagents (Amersham Corp.).
Enzymatic Activity of Matrix
Metalloproteinase-1 In Vitro and In Vivo
Human MMP-1, which was expressed in vitro, was
tested for its enzymatic activity against type I collagen at
37°C. Collagen type I derived from rat tail (30 g; BD
Biosciences, Bedford, MA) was incubated for 12 hours with
supernatant of Rat-2 fibroblasts infected with Ad5MMP-1 or
Ad5LacZ.27 Reactions were stopped by adding SDS-polyacryl-
amide gel electrophoresis (PAGE) loading buffer with 20
mmol/L of EDTA (pH 8.0), and the products were analyzed on
SDS-PAGE stained with Coomassie stain (Bio-Rad Laborato-
ries, Hercules, CA). Collagen was then examined for digestion
into smaller fragments. In this study, APMA (1 mmol/L) was
added to some supernatants to convert pro–MMP-1 to its
active form, and 20 mmol/L of EDTA (pH 8.0) was added to
some reactions in advance to suppress MMP-1 activity.
The enzymatic activity of human MMP-1 in vivo was
accessed in a liver fibrosis model established by bile duct
ligation. With male Sprague–Dawley rats (250 g body weight),
the bile duct was surgically ligated under anesthesia.28 Ten
days later, the rats were injected through the tail vein with
5  109 pfu of Ad5MMP-1 or control virus (Ad5LacZ). Livers
were harvested 2 days after the virus injection, and proteins
were extracted with 6 mol/L of guanidine HCl for 3 days.
Proteins were then dialyzed against phosphate-buffered saline
(PBS) for 2 h, and then SDS was added to a final concentration
of 1% and protein concentrations were determined by Brad-
ford assay. A total of 50 g of protein was run under reducing
conditions on 7.5% gel, and Western blot was performed with
anti-collagen 1(I) antibody (dilution 1:1000; Biodesign In-
ternational, Saco, ME).
Induction of Liver Fibrosis With
Thioacetamide in the Rat
Thioacetamide (TAA) (200 mg/kg body weight) was
injected intraperitoneally 3 times a week into male Sprague–
Dawley rats (100 g body weight) for 4 or 7 weeks. The
administration of TAA was stopped before the therapy to
prevent any confusion with drug delivery or metabolism,
which would be of concern if we were giving the fibrogenic
agent at the same time as the therapy. After withdrawal of
TAA treatment of 7 weeks, hepatic fibrosis persisted at least
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for 2 months; this is similar to the results of a previous
report.29,30
Adenoviral Infection and Tissue Sampling
Ad5MMP-1 or Ad5LacZ was stored in 10% glycerol
and was then twice dialyzed against a solution containing 10
mmol/L of Tris (pH 8.0), 1 mmol/L of MgCl2 , and 140
mmol/L of NaCl for 2 hours just before use. One week after
finishing the treatment of TAA, rats were infected once with
recombinant adenovirus (5  109 pfu per rat, 0.5 mL) by
intravenous injection through tail veins. At 2 or 4 weeks after
the adenoviral infection, rats were killed, and liver tissues were
examined. Animals were injected with bromodeoxyuridine
(BrdU) (100 mg/kg; Sigma Chemical Co., St. Louis, MO) and
killed 1 hour later. Blood samples were collected by puncture
of the abdominal aorta, and serum was stored at 80°C until
analysis. Samples of the liver were snap-frozen in liquid nitro-
gen or were fixed in 10% buffered formalin for subsequent
histological analysis. The efficiency of adenoviral gene transfer
to the liver in vivo was examined by X-gal staining31 of
the liver infected with Ad5LacZ (5  109 pfu per rat); more
than 90% of hepatocytes and approximately 25% of nonparen-
chymal cells were positive for -galactosidase (data not
shown).
Histology and Immunohistochemistry
The liver specimens were fixed overnight in 10%
phosphate-buffered formaldehyde, embedded in paraffin, and
stained with H & E and Masson’s trichrome. For immunohis-
tochemical studies, sections were deparaffinized in xylene and
rehydrated in alcohol. A DAKO Envision system (DAKO
Corp., Carpinteria, CA) was used for -smooth muscle actin
(-SMA), desmin, and BrdU immunostaining. After blocking
of endogenous peroxidase with peroxidase-blocking agent, sec-
tions were incubated with mouse anti–-SMA (1:200; DAKO)
or mouse anti-desmin (DAKO) for 10 minutes at 25°C. After
two 3-minute washes in PBS, sections were incubated with
labeled polymer (peroxidase-labeled polymer conjugated to
goat anti-rabbit and goat anti-mouse immunoglobulins) for 10
minutes at 25°C. Sections were then washed twice with PBS,
incubated with 3,3-diaminobenzidine substrate chromogen for
8 minutes, washed with distilled water, incubated with 3,3-
diaminobenzidine enhancer (Innovex Biosciences, Richmond,
CA) for 5 minutes, and washed with distilled water before
counterstaining with hematoxylin. For BrdU assay, deparaf-
finized sections were incubated in 4N HCl for 20 minutes at
37°C and washed several times with distilled water and 1
PBS. After blocking of endogenous peroxidase with peroxidase-
blocking agent, sections were incubated with mouse monoclo-
nal anti-BrdU antibody (1:200 in PBS containing 5% bovine
serum albumin; Sigma Chemical Co.) for 10 min at 25°C. The
procedure was the same for -SMA and desmin staining.
Semiquantitative image analysis was also performed for the
-SMA–positive area in the liver tissues according to the
method described below, because to count -SMA–positive
cells was sometimes difficult even under high-power fields.
Sirius Red Staining and Image Analysis
To semiquantitatively determine collagen contents in
liver tissues, deparaffinized liver sections were incubated for 15
minutes in a solution of saturated picric acid containing 0.1%
Fast Green FCF, followed by incubation for 40 minutes in
0.1% Sirius red in saturated picric acid.32 Stained slides were
washed in running distilled water, dehydrated, mounted, and
examined by light microscopy. Microscopic pictures of the
stained liver specimens were taken (40), and positive signals
were analyzed with the freeware image analysis program NIH
Image 1.61 (http://rsb.info.nih.gov/nih-image/index.html). By
using the NIH Image program, the signals from the gray scale
were quantified, and the mean area of fibrosis was calculated as
an average percentage for 5 fields (40) from each animal.
Quantification of Hydroxyproline
in Liver Tissues
The rat liver tissues were stored at 80°C until use.
Each tissue was thawed on ice and minced manually by using
a razor blade and then pulverized to fine powder in liquid
nitrogen by a Spex Freezer Mill (SPEX CertiPrep, Metuchen,
NJ). The samples were washed with cold PBS several times and
then with cold distilled water and lyophilized. The dried
samples were hydrolyzed with 6N HCl in vacuo, after flushing
with nitrogen, for 22 hours at 110°C. The hydrolysates were
dried in a speed vacuum concentrator, and the residues were
dissolved in distilled water. The hydrolysates were filtered
through 0.22-m Millipore filters. The hydroxyproline con-
tents in the rat liver samples were determined by a high-
performance liquid chromatography method.33
Measurement of Dry Liver Weight
Whole liver weight was measured in each animal at
death; a part of the liver was collected, and its wet weight was
determined. The rest of the liver was used for other assays. The
liver tissue was dried at 80°C for 72 hours, and its dry weight
was determined. Dry whole liver weight was calculated as (wet
whole liver weight)/(wet liver tissue weight)  (dry liver tissue
weight).
Liver Function Test
Blood samples were collected from each animal by
aortic puncture before killing. Serum was stored at 80°C
until measurement of alanine aminotransferase (ALT), biliru-
bin, and albumin by automatic analysis.
Statistics
Analysis of variance and Dunnett’s post hoc test were
used for determination of statistical significance. Significance
was defined as a P value of 0.05.
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Results
Assessment of a Recombinant Adenovirus
Expressing Human Pro–MMP-1
Rat-2 fibroblasts were infected with the
Ad5MMP-1 adenovirus (multiplicity of infection, 20),
and then the culture medium was collected after 48
hours and prepared for Western blot analysis. By using
an anti-human MMP-1 antibody, which detects both
pro–MMP-1 and MMP-1, the expressed human pro–
MMP-1 (51 kilodaltons) was identified in the culture
medium (Figure 1A, left lane). After incubation with
APMA (1 mmol/L) at 37°C for 4 hours, the pro–MMP-1
band shifted lower (41 kilodaltons), which was consistent
with the active form of human MMP-1 (Figure 1A, right
lane). Enzymatic activity of expressed human MMP-1 in
vitro was shown by its ability to digest type I collagen
into smaller fragments (Figure 1B, lane 8). Adding
EDTA to the incubation mixtures clearly blocked the
enzymatic activity (Figure 1B, lane 9), consistent with
this enzyme’s being a metalloproteinase. Western blot
analysis with liver tissue homogenates showed that the
delivery of human pro–MMP-1 complementary DNA by
Ad5MMP-1 (5  109 pfu per rat intravenously) success-
fully expressed pro–MMP-1 in all livers infected with
Ad5MMP-1 (Figure 1C, lanes 1–4). Moreover, the active
form of MMP-1 (41 kilodaltons) was also detected in this
assay, indicating that the expressed pro–MMP-1 protein
was gradually converted to the active form in vivo (Fig-
ure 1C ). These 2 bands were not detected in control or
Ad5LacZ-infected rats (data not shown). The enzymatic
Figure 1. Expression of human pro–MMP-1 and MMP-1 in vitro and in vivo. (A) Culture medium was collected from Rat-2 fibroblasts 48 hours
after infection with Ad5MMP-1, as described in Methods. Expression of human pro–MMP-1 protein in the medium was assessed by Western
blotting with anti-human MMP-1 antibody, which detects both pro–MMP-1 and MMP-1. In addition to human pro–MMP-1 (51 kilodaltons), an active
form of human MMP-1 (41 kilodaltons) was detected after incubation with p-aminophenylmercuric acetate (APMA; 1 mmol/L) at 37°C for 4 hours.
(B) Type I collagen (30 g) was incubated for 12 hours at 37°C with culture medium of Rat-2 fibroblasts infected with Ad5MMP-1 or Ad5LacZ.
The products were separated on SDS-PAGE and stained with Coomassie blue. APMA was added to some incubation mixtures to activate MMP-1,
and EDTA was used to block MMP-1 activity. Lane 1 was the original substrate, collagen type I. (C) Male Sprague–Dawley rats (250–280 g) were
infected with Ad5MMP-1 (5 109 pfu per rat intravenously) for 72 hours, and liver tissues were collected. Western blotting for human pro–MMP-1
and MMP-1 was performed by using liver homogenate as described in Methods. Lanes 1–4 were liver homogenate collected from 4 individual
rats infected with Ad5MMP-1. (D) Bile ducts were ligated in rats, and after 10 days the rats were injected through the tail veins with 5  109 pfu
of Ad5MMP-1 or control virus (Ad5LacZ). Livers were harvested 2 days after the virus injection, and proteins were prepared as described in
Methods. Western blot was performed with anti-collagen 1(I) antibody. Lane 1, normal rat liver; lane 2, bile duct–ligated liver with control virus;
lane 3, bile duct–ligated liver with Ad5MMP-1; lane 4, medium of rat fibroblasts. Migration of pro–collagen 1(I) is indicated by an arrow.
Higher-molecular-weight collagen species, which represent cross-linked type I collagen, are indicated by the bracket, and a degradation product
of type I collagen is indicated by an asterisk (lane 3). Representative data of 3 repeated experiments are shown.
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activity of MMP-1 in vivo was accessed in a bile duct
ligation model of hepatic fibrosis by Western blot with
anti-collagen 1(I) antibody, as described in Methods.
Higher-molecular-weight collagen species (indicated by
the bracket in Figure 1D), which represent cross-linked
type I collagen, were detected in the fibrotic liver treated
with the control adenovirus (AdLacZ), whereas a very
small amount of these collagen species was observed in
normal rat liver. However, in the fibrotic liver infected
with Ad5MMP-1, these cross-linked type I collagen
species were dramatically decreased, and a degradation
product of type I collagen (Figure 1D, asterisk) was
detected. Histologically, the short-term bile duct liga-
tion produced, as expected, equal bile duct proliferation
but minimal fibrosis in both Ad5MMP-1– and
Ad5LacZ-infected animals (data not shown). These data
indicated that pro–MMP-1 transferred in vivo was acti-
vated and degraded cross-linked type I collagen in fi-
brotic liver.
Thioacetamide Treatment Established
Persistent Hepatic Fibrosis in the Rat
After treatment with TAA (200 mg/kg body
weight) for 4 weeks, mild fibrosis was observed in the
liver, and the fibrosis persisted until the end of this
experiment (5 weeks after the removal of TAA treat-
ment) (Figure 2A and B). TAA treatment for 7 weeks
induced more advanced hepatic fibrosis, and so-called
regenerating lobules were often observed (Figure 2C,
asterisk). The fibrosis observed in the 7-week TAA
model was almost unchanged until the end of this study
(Figure 2D). We assessed 6 animals in each experiment
and obtained similar results in each animal. These results
and those of previous studies29,30 show that TAA-in-
duced liver fibrosis is a clinically relevant model for the
treatment of stable fibrosis.
Histological Changes of Liver Fibrosis After
the Adenoviral Infection
One week after their last treatment, TAA-treated
rats were infected with Ad5MMP-1 or Ad5LacZ (5 
109 pfu per rat). Histological change of the liver was
examined at 2 and 4 weeks after the infection. The
control Ad5LacZ had no obvious effect on the established
liver fibrosis, which received TAA treatment for 7 weeks
(Figure 3A and B). After the Ad5MMP-1 infection,
fibrosis was significantly attenuated by 2 weeks and
remained attenuated by 4 weeks, as indicated by Mas-
son’s trichrome staining (Figure 3C and D). In the rats
treated with TAA for 4 weeks, mild hepatic fibrosis in
the interlobular spaces was observed, and the fibrosis
almost disappeared at 2 weeks after the infection with
Ad5MMP-1, but not with Ad5LacZ. The fibrosis re-
mained resolved even at 4 weeks (data not shown).
Quantitative Analysis of Liver Fibrosis After
the Adenoviral Infection
Semiquantitative analysis of liver fibrosis was per-
formed by Sirius red staining and image analysis. Red color
area observed in the liver after TAA treatment for 7 weeks
(Figure 4A) was obviously decreased in Ad5MMP-1–in-
fected rats at 2 weeks (Figure 4B), whereas Ad5LacZ did not
affect the fibrosis (Figure 4C). Image analysis showed that
the percentage of fibrosis area in the liver was dramatically
decreased by MMP-1 expression (Figure 4D). Quantifica-
tion of hydroxyproline in the liver by high-performance
liquid chromatography confirmed that MMP-1 expression
in the liver significantly attenuated collagen deposition in
this model (Figure 4E). Although the decrease in hy-
droxyproline content was less striking than that observed
with Sirius red staining, the hydroxyproline assay measures
undegraded and degraded collagen, and similar discrepan-
cies between these types of measurements have been previ-
ously described.22,34,35
Overexpression of MMP-1 Decreased the
Number of Activated Hepatic Stellate Cells
After TAA treatment for 7 weeks, the area of
-SMA–positive cells (a marker of activated HSCs) in the
liver markedly increased (Figure 5A), especially in the
interlobular space, where deposition of fibrillar collagens
was observed (Figure 4A). In Ad5MMP-1–infected rats, the
-SMA–positive area dramatically decreased at 2 weeks
(Figure 5B), whereas infection with Ad5LacZ had no effect
(Figure 5C). A significant decrease in the -SMA–positive
area was observed only in Ad5MMP-1–infected animals
(Figure 5G). This result indicated that degradation of fibril-
lar collagens because of MMP-1 overexpression in the liver
leads to a decrease in the number of activated HSCs. To
further examine whether activated HSCs disappeared or
were transformed to quiescent HSCs, liver tissues under-
went an immunostaining of desmin, a marker of all HSCs.
The number of desmin-positive cells in the liver was also
dramatically decreased in Ad5MMP-1–infected rats (Figure
5E) compared with that in uninfected and Ad5LacZ-in-
fected rats (Figure 5D and F ).
MMP-1 Expression in the Liver Induced
Hepatocyte Proliferation
Histological analysis of the TAA-treated liver
tissues with H & E staining showed disarrangement of
the hepatic trabecula and heterogeneity in the size of
hepatocytes without obvious inflammatory changes only
in Ad5MMP-1–infected rats at 2 weeks (Figure 6B,
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white triangles). From these results, we speculated that
hepatocyte proliferation was induced by MMP-1 overex-
pression in the liver independent of adenoviral infection,
because the control adenovirus Ad5LacZ had no effect on
histology (Figure 6C ). The morphological changes of
hepatocytes in Ad5MMP-1–infected rats resolved at 4
weeks after the infection (Figure 6E ). BrdU staining of
the TAA-treated liver confirmed the proliferative effect
of MMP-1 overexpression (Figure 7). Namely, increased
BrdU-positive hepatocytes were observed only in
Ad5MMP-1–infected (5%  2.6%) (Figure 7B), but not
in uninfected or Ad5LacZ-infected, rats at 2 weeks (0.2%
 0.1% and 0.3%  0.2%, respectively) (Figure 7A and
C ). However, the positive cells in the Ad5MMP-1–
treated liver almost disappeared by 4 weeks (1.0% 
0.3%; Figure 7D), consistent with the normalization of
hepatocyte morphology in H & E staining at 4 weeks
(Figure 6E ).
At both time points after TAA treatment (4 and 7
weeks), dry liver weight in Ad5MMP-1–infected rats sig-
nificantly increased at 2 weeks compared with that in
Ad5LacZ-infected and uninfected rats (P  0.01) (Figure
8). The increased dry liver weight in Ad5MMP-1–treated
rats tended to decrease by 4 weeks after infection, although
a significant increase in the weight compared with that in
Ad5LacZ-treated rats persisted in the 7-week TAA model
(Figure 8). Thus, the proliferative effect on hepatocytes by
MMP-1 that was observed at 2 weeks gradually disappeared
by 4 weeks after the infection.
MMP-1 Expression in the Liver Induced
Transient Liver Injury
Measurement of the liver-specific enzyme ALT in
the serum of the rats showed that MMP-1 expression in the
liver transiently induced a significant increase in serumALT
(200 IU/L; P  0.05), which returned to almost normal
by 4 weeks after infection (Figure 9). These data imply that
the expression of MMP-1 also causes moderate hepatocyte
cell damage. However, serum total bilirubin did not
change significantly even after the TAA treatment and
adenoviral infections in this study (TAA only, 0.13 
0.06 mg/dL; TAA plus Ad5MMP-1, 0.25  0.06 mg/
dL; and TAA plus Ad5LacZ, 0.13  0.05 mg/dL, re-
spectively). Serum albumin levels at death were also not
significantly different even after adenoviral treatment
(TAA only, 3.77  0.35 mg/dL; TAA plus Ad5MMP-1,
4.00  0.22 mg/dL; and TAA plus Ad5LacZ, 4.13 
0.24 mg/dL, respectively). From these results, we could
conclude that TAA treatment induced stable fibrosis
without causing severe liver failure.
Discussion
Advanced liver fibrosis and cirrhosis are believed to
form irreversible scars, characterized by increased depo-
sition and altered composition of ECM. The only cura-
tive treatment of end-stage cirrhosis is transplantation,
which is limited by the number of donor organs. Several
approaches have successfully prevented the progression of
liver fibrosis in animal models.15–21 However, because
fibrotic liver disease may not present clinically until an
advanced or cirrhotic stage, the possibility of reversing
established fibrosis is an essential issue. Some investiga-
tors have reported improvement in liver fibrosis and
cirrhosis in selective patients with effective antiviral
therapies in chronic viral hepatitis14,36 and with surgical
decompression of secondary biliary fibrosis,37 suggesting
a capacity for recovery even from established cirrhosis.
We efficiently delivered to the liver a recombinant
adenovirus expressing human pro–MMP-1 that was con-
verted to the active form in situ with functional colla-
genase activity (Figure 1C and D) and degraded type I
collagen to produce a small fragment (Figure 1D). We
did not analyze the mechanism for conversion of pro–
MMP-1 to the active form in this study. However,
plasmin generated from plasminogen by plasminogen
activator (uPA) possibly plays an important role in this
mechanism.38 Although rats do not normally express
MMP-1, we used human MMP-1 so that we could begin
to access its therapeutic effectiveness for human cirrhosis.
Š
Figure 2. Liver fibrosis induced by thioacetamide (TAA) in the rat is persistent. Liver tissues were stained with Masson’s trichrome after
treatment with TAA (200 mg/kg) for 4 weeks (A and B) or 7 weeks (C and D). Livers were collected from rats 3 weeks (A and C) or 5 weeks (B
and D) after the withdrawal of TAA treatment. Mild (A) or advanced (C) liver fibrosis observed at 3 weeks after the withdrawal of TAA did not
spontaneously recover by the end of this experiment (B and D). Each figure was a representative picture of 6 individual animals in each group.
White triangles indicate portal areas, and asterisks represent pseudo- or regenerating lobules. Original magnification was 200. Magnification
of the inset (C and D) was 20.
Figure 3. Expression of human MMP-1 in the liver dramatically attenuated established fibrosis. Liver tissues treated with TAA (200 mg/kg) for
7 weeks were stained with Masson’s trichrome at 2 (A and C) or 4 (B and D) weeks after the adenoviral infections. Liver tissues were collected
from Ad5LacZ-infected (A and B) or Ad5MMP-1 infected (C and D) rats. Ad5LacZ infection had no effect on TAA-induced liver fibrosis, whereas
expression of MMP-1 attenuated liver fibrosis at 2 weeks (C), and the attenuated fibrosis remained for 4 weeks (D). Each figure was a
representative picture of 6 individual animals in each group. White triangles indicate portal areas, and asterisks represent pseudo- or
regenerating lobules. Original magnification was 200. Magnification of the inset (C and D) was 20.
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However, because we only gave a single dose of either
virus (Ad5MMP-1 or Ad5LacZ), we did not expect an
anamnestic response as in a rechallenge experiment.39
Recent studies from our laboratory40 and others41 have
also used a single dose of an adenovirus to successfully
deliver a therapeutic protein to the liver, although the
possibility still remains that differences in the immuno-
genicity of bacterial -galactosidase and delivered pro-
teins could affect the results.
Type I collagen consists of 3 polypeptide chains, each
with a molecular mass of approximately 95 kilodaltons,
which self-associate into a triple-helical structure.
MMP-1 is able to cleave all 3 chains of type I collagen at
a single locus between 1 Gly-Ile in each 1 chain and 1
Gly-Leu in the 2 chain,42 and the fragments generated
are melted below 37°C.43 In our study, established col-
lagen fibers in the liver were dramatically reduced by
MMP-1 expression without major inflammation (Figure
4), indicating that the MMP-1 was enzymatically active
but did not cause severe hepatic injury. The histological
data on the fibrotic response (Figure 4A–D) seemed
much more striking than the quantitative data on hy-
droxyproline content (Figure 4E ) in this study. This
discrepancy between morphometric analysis and quanti-
tative hydroxyproline analysis has also been reported in
some previous studies.22,34,35 One possible explanation is
that some of the degraded collagen fragments will still be
in the liver and will be measured as hydroxyproline.
Although apparent histological change was observed in
the liver, as shown in Figures 3 and 6, no obvious injury
in other organs—such as lung, kidney, spleen, heart, and
blood vessels—was detected in this study (data not
shown). One possible explanation is that secreted pro–
MMP-1 is gradually converted to the active form in situ,
as indicated by Western blot (Figure 1C ), and degrades
collagens in the liver, whereas any MMP-1 that over-
flowed out of the liver binds its inhibitor, TIMP. More-
over, Western blot with homogenates from those organs
showed no significant expression of MMP-1 (data not
shown). Our results are consistent with our underlying
hypothesis that failure to resolve the fibrous scar in
advanced liver fibrosis results from the imbalance be-
tween too few interstitial collagenases and too much
ECM and too many TIMPs.
In addition to the reduction of collagen fibers in the
liver, we observed fewer activated HSCs after MMP-1
expression (Figure 5B and G). Fewer activated HSCs
during spontaneous resolution of an experimental liver
fibrosis have been reported,44 and apoptosis of HSCs was
proposed as the mechanism. Because the number of
desmin-positive cells was also decreased in Ad5MMP-1
rats in our study (Figure 5E ), activated HSCs were not
transformed to their quiescent forms, but rather disap-
peared. HSCs have several integrins on their surface,
including 11, 21, v1, 51, and 64.45,46
Š
Figure 4. Hepatic collagen content was significantly reduced by Ad5MMP-1 infection. Liver tissues treated with TAA (200 mg/kg) for 7 weeks
were stained with Sirius red at 2 weeks after Ad5MMP-1 (B) or Ad5LacZ (C) infection, or without infection (A), as described in Methods. Collagen
fibers are represented as a red area. Each figure was a representative picture of 6 individual animals in each group. Image analysis of the area
in the liver, which was performed as described in Methods, showed a significant decrease in the area only in Ad5MMP-1–infected rats at 2 and
4 weeks after infection (D) (P  0.01). Quantitative measurement of hydroxyproline in the liver at 2 weeks showed a significant decrease only
in the Ad5MMP-1–infected rats (E). Six animals were examined in each experimental group. The original magnification for Sirius red staining was
40. *P  0.05 compared with uninfected or Ad5LacZ-infected livers.
Figure 5. The number of activated hepatic stellate cells in the liver was reduced by MMP-1 gene delivery. Immunostaining for -smooth muscle
actin (-SMA) (A–C) and desmin (D–E) was performed in the liver from rats treated with TAA (200 mg/kg) for 7 weeks. (A and D) Uninfected, (B
and E) Ad5MMP-1–infected, or (C and F ) Ad5LacZ-infected livers at 2 weeks after the infection are shown. An increased number of
-SMA–positive cells were observed in uninfected (A) or Ad5LacZ-infected (C) livers, whereas only a few -SMA–positive cells were detected in
Ad5MMP-1–infected liver, except for smooth muscle cells in blood vessels (B). The number of desmin-positive cells was also decreased only in
Ad5MMP-1–infected livers (E). Each figure was a representative picture of 6 individual animals in each group. White triangles indicate portal
areas, and asterisks represent pseudo- or regenerating lobules. The original magnification was 100 (A–C) or 200 (D–F ). The -SMA–positive
area was also semiquantified by image analysis with NIH Image 1.61, and a significant decrease was detected only in Ad5MMP-1–infected rats
(G). Six animals were examined in each experimental group.
Figure 5—Continued
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Among them, major integrins for native collagen type I
are 11 and 21.47,48 Moreover, activated HSCs also
have the nonintegrin collagen receptor, discoidin domain
receptor-2.3 Previous in vitro studies have reported that
HSCs are activated on collagen type I, whereas they are
quiescent on Matrigel (BD Biosciences, San Jose, CA).49
Because native collagen I is degraded by MMP-1 and
removed from the liver in our model, activation of HSCs
could be attenuated according to detachment from native
collagen I. Although we did not investigate whether apo-
ptosis of HSCs occurred, we noted that MMP-1 expression
produced a marked decrease in both total and activated
HSCs. Thus, we speculate that reducing native collagen
type I in vivo by MMP-1 expression could eliminate the
activated HSCs by apoptosis.
Another key observation in this study was that pro-
liferation of hepatocytes was induced by MMP-1 expres-
sion in the liver. The proliferative effect on hepatocytes
was still obvious at 2 weeks after the adenoviral infection
(Figures 6B and 7B) but had almost disappeared by 4
weeks (Figures 6E and 7D). Toxicity of the viral proteins
is of concern with these first-generation adenoviral vec-
tors, including the induction of immune responses.50,51
In this study, 2 different control groups were consis-
tently used: non–viral-infected and control Ad5LacZ-
infected animals. Using these control groups in the ex-
periments, we were able to minimize the adenoviral
effect and differentiate it from the MMP-1 effect. More-
over, this proliferation is not specific to the fibrotic liver,
because we have observed the same proliferative effect of
MMP-1 on hepatocytes when MMP-1 was expressed in
normal rat liver (T. Nishio and Y. Iimuro, unpublished
observations). When we delivered human MMP-1 and
LacZ genes to normal rat liver by using the same adeno-
viral vectors, we observed hepatocyte proliferation only
in Ad5MMP-1–infected, but not in Ad5LacZ-infected,
rats. Proliferation of hepatocytes started around 24 hours
and had almost stopped by 1 week, accompanied by
cytoplasmic accumulation of -catenin and a transient
decrease in the protein expression of focal adhesion kinase
and integrin-linked kinase (data not shown). We also
detected a transient increase in serum ALT levels after
Figure 8. Dry liver weight was significantly increased after Ad5MMP-1 infection. Dry liver weight in uninfected (white bars), Ad5MMP-1–infected (black
bars), and Ad5LacZ-infected (hatched bars) groups was determined at 2 or 4 weeks after the adenoviral infection, as described in Methods. Six animals
were examined in each experimental group. *P  0.05 compared with uninfected control animals. #P  0.05 compared with Ad5LacZ-infected animals.
Š
Figure 6. MMP-1 expression induced morphological change in hepatocytes. After TAA treatment, uninfected (A and D), Ad5MMP-1–infected (B
and E), or Ad5LacZ-infected (C and F ) livers were stained with H & E at 2 weeks (A–C) or 4 weeks (D–F ) after infection. In addition to reduced
fibrosis, morphological changes in hepatocytes, such as disarrangement of the hepatic trabecula (B; white triangles) and heterogeneity in the
size of hepatocytes (B, inset; black triangles), were detected predominantly around the portal vein area (P) only in Ad5MMP-1–infected rats at
2 weeks (B). The morphological change, however, almost disappeared by 4 weeks after the infection (E). Each figure was a representative picture
of 6 individual animals in each group. The original magnification was 200, or 400 for the insets. C, central vein.
Figure 7. DNA synthesis was detected in hepatocytes at 2 weeks after MMP-1 infection. (A) Uninfected, (B) Ad5MMP-1–infected, or (C)
Ad5LacZ-infected livers underwent BrdU staining at 2 weeks after infection to detect cells newly synthesizing DNA, as described in Methods. Only
in Ad5MMP-1–infected liver were 5% 2.6% of hepatocytes positive for BrdU at 2 weeks (B). This DNA synthesis observed in Ad5MMP-1–infected
liver at 2 weeks almost disappeared at 4 weeks after infection (D). Each figure was a representative picture of 6 individual animals in each group.
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MMP-1 expression; these started to increase around 96
hours, peaked around 1 week, and returned to normal
levels by 2 weeks. Thus, MMP-1 produced hepatocyte
proliferation followed by moderate cellular damage.
Other investigators have reported a similar phenomenon
in the skin.52 They examined the effect of MMP-1 over-
expression in the skin by using a series of transgenic
mice, in which the human tissue collagenase gene was
expressed in the suprabasal layer of the skin epidermis.
The skin showed hyperproliferative changes, such as
acanthosis, hyperkeratosis, and epidermal hyperplasia,
but no obvious inflammation was observed. However,
overexpression of TIMP-1 in the liver has been reported
to block neoplastic proliferation of liver tumors.53,54
However, the molecular mechanisms for the prolifer-
ative effect of MMP-1 overexpression still remain elusive.
In a previous report,55 prominent hepatocyte prolifera-
tion was induced by intraportal infusion of collagenase,
followed by a treatment with hepatocyte growth factor.
Therefore, it is possible in our model that several growth
factors bound to hepatic ECM, such as hepatocyte
growth factor,56 are freed from ECM by MMP-1 and that
the activated growth factors facilitate hepatocyte prolif-
eration. Alternatively, changes in interaction between
ECM and hepatocyte possibly stimulate hepatocyte pro-
liferation directly because hepatocytes are known to be
responsive to the biophysical state of ECM.57
Despite the beneficial effects of MMP-1, including
attenuation of established liver fibrosis and stimulation
of hepatocyte proliferation, its expression also caused
mild liver injury, indicated by a transient increase in
serum ALT levels (Figure 9). We have less insight into
the mechanism by which MMP-1 expression caused liver
damage. Apoptosis should not be a major reason for this
phenomenon, because we detected only a few apoptotic
bodies in the liver by H & E staining even at 2 weeks
after Ad5MMP-1 infection. Direct damage to the hepa-
tocyte cell membrane because of prolonged exposure to
an active form of MMP-1 possibly participates in the
mechanism, although major inflammation due to hepa-
tocyte necrosis was not detected. Although uninfected
and control adenoviral-infected rats did not have this
transient liver injury, we cannot exclude the possibility
that this structural reorganization was induced indepen-
dently of collagenase activity.
In conclusion, we shifted the balance between profi-
brogenesis (ECM and TIMPs) and antifibrogenesis (col-
lagenases) in a model of stable hepatic fibrosis. Transient
expression of human pro–MMP-1 in the liver diminished
established hepatic fibrosis without major hepatic injury
or inflammation, despite a transient increase in serum
ALT levels. Although prolonged MMP-1 expression in
transgenic animals may have a carcinogenic effect,52 gene
transfer with an adenoviral vector is limited, and mor-
Figure 9. Effect of TAA treatment and adenoviral infections on serum ALT levels. Samples were collected from each animal at death, and serum
ALT levels were automatically determined by enzymatic analysis. Six animals were examined in each experimental group. *P  0.05 compared
with uninfected or Ad5LacZ-infected animals.
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phological changes in hepatocytes returned to almost
normal by 4 weeks (Figure 6B versus 6E ). Thus, both
collagen degradation and transient cellular damage me-
diated by active MMP-1 may be beneficial to the remark-
able resolution of stable fibrosis.
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